All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Multiple Myeloma Hub Virtual Symposium 2024: Current and future perspectives for bispecific antibodies
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” Amrita Krishnan, City of Hope Comprehensive Cancer Center, Duarte, US, delivered a presentation on novel strategies using bispecific antibodies beyond B-cell maturation antigen (BCMA)-directed therapies.
Krishnan discussed alternative targets for bispecific antibodies on myeloma cells, including G-protein coupled receptor family C group 5 member D (GPRC5D) and Fc receptor-homolog 5 (FcRH5), touching on a new development in dual-targeting trispecific antibodies (Figure 1). Krishnan presented clinical data from approved and investigational non-BCMA targeting agents, as well as highlighting the optimal sequencing in the myeloma treatment paradigm (Figure 2).
Figure 1. Mechanism of action of JNJ-79635322, a potential first-in-class trispecific antibody targeting BCMA, GPRC5D, and CD3
BCMA, B-cell maturation antigen; GPRC5D, G protein–coupled receptor family C group 5 member D; IFN-γ, interferon-gamma; IgG, immunoglobulin G; IL, interleukin; MM, multiple myeloma; TNF, tumor necrosis factor.
*Adapted from Pillarisetti, et al.1
Figure 2. Response rates with CAR T-cell and subsequent therapy after talquetamab in the MonumenTAL-1 trial*
BsAb, bispecific antibody; CAR, chimeric antigen receptor; CR, complete response; GPRC5D, G protein–coupled receptor, class C group 5 member D; IMiD, immunomodulatory agent; mAb, monoclonal antibody; ORR, overall response rate; PI, proteosome inhibitor; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.
*Data from Sanchez.2
This independent medical activity was funded by Janssen and Bristol Myers Squibb. All content was developed independently by the faculty. The funders were allowed no influence on the content of this activity.
Multiple Myeloma Hub Virtual Symposium 2024: Current and future perspectives for bispecific antibodies
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox